Fibromun is a biopharmaceutical product, proprietary to Philogen, studied for the treatment of advanced soft tissue sarcoma (STS) and glioblastoma, the results of the Phase-3 trial for STS are anticipated between March and June 2025. Read more: https://pharma.economictimes.indiatimes.com/news/research-and-development/sun-pharma-philogen-complete-patient-enrollment-for-cancer-drug-phase-3-trials-results-expected-by-q1-fy26/117982278